IFITM2 antibody (AA 1-100)

Catalog No. ABIN7267949

Product Details anti-IFITM2 Antibody

Target: IFITM2 (Interferon Induced Transmembrane Protein 2 (IFITM2))

Binding Specificity: AA 1-100

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This IFITM2 antibody is un-conjugated

Application: Western Blotting (WB)

Purpose: IFITM2 Rabbit pAb

Sequence: MNHIVQTFSP VNSGQPPNYE MLKEEQEVAM LGVPHNPAPP MSTVIHIRSE TSVPDHVVWS LFNTLFMNTC CLGFIAFAYS VKSRDRKMVG DVTGAQAYAS

Cross-Reactivity: Human

Characteristics: Polyclonal Antibodies

Purification: Affinity purification

Immunogen: A synthetic peptide corresponding to a sequence within amino acids 1-100 of human IFITM2 (NP_006426.2).

Isotype: IgG

Application Details

Application Notes: WB,1:500 - 1:2000

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: PBS with 0.02 % sodium azide,50 % glycerol, pH 7.3.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store at -20°C. Avoid freeze / thaw cycles.

Target Details for IFITM2

Target: IFITM2 (Interferon Induced Transmembrane Protein 2 (IFITM2))

Alternative Name: IFITM2 (IFITM2 Products)

Synonyms: 1-8D antibody, DSPA2c antibody, Ifitm3l antibody, fragilis3 antibody, mil-3 antibody, Ifitml antibody, interferon induced transmembrane protein 2 antibody, IFITM2 antibody, Ifitm2 antibody

Background: IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol. Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2, Marburg virus (MARV, Ebola virus (EBOV, Dengue virus (DNV, West Nile virus (WNV, human immunodeficiency virus type 1 (HIV-1, hepatitis C virus (HCV and vesicular stomatitis virus (VSV. Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry, SARS-CoV and SARS-CoV-2 S protein-mediated viral entry and VSV G protein-mediated viral entry. Induces cell cycle arrest and mediates apoptosis by caspase activation and in p53-independent manner. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation. IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome.,IFITM2,1-8D,DSPA2c,Cancer,Tumor immunology,Tumor-associated antigens,Immunology & Inflammation,Cytokines,Interferons,Cell Intrinsic Innate Immunity Signaling Pathway,IFITM2

Molecular Weight: 14kDa

Gene ID: 10581

UniProt: Q01629